AQST Annual Revenue
$50.58 M
+$2.90 M+6.09%
31 December 2023
Summary:
As of January 23, 2025, AQST annual revenue is $50.58 million, with the most recent change of +$2.90 million (+6.09%) on December 31, 2023. During the last 3 years, it has risen by +$4.73 million (+10.33%). AQST annual revenue is now -24.98% below its all-time high of $67.43 million, reached on December 31, 2018.AQST Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AQST Quarterly Revenue
$13.54 M
-$6.56 M-32.62%
30 September 2024
Summary:
As of January 23, 2025, AQST quarterly revenue is $13.54 million, with the most recent change of -$6.56 million (-32.62%) on September 30, 2024. Over the past year, it has increased by +$540.00 thousand (+4.15%). AQST quarterly revenue is now -50.11% below its all-time high of $27.15 million, reached on September 30, 2017.AQST Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AQST TTM Revenue
$58.90 M
+$540.00 K+0.93%
30 September 2024
Summary:
As of January 23, 2025, AQST TTM revenue is $58.90 million, with the most recent change of +$540.00 thousand (+0.93%) on September 30, 2024. Over the past year, it has increased by +$10.84 million (+22.56%). AQST TTM revenue is now -23.19% below its all-time high of $76.68 million, reached on June 30, 2018.AQST TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AQST Revenue Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.1% | +4.2% | +22.6% |
| 3 y3 years | +10.3% | +4.2% | +22.6% |
| 5 y5 years | -25.0% | +4.2% | +22.6% |
AQST Revenue High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -0.5% | +6.1% | -32.6% | +26.8% | at high | +26.6% |
| 5 y | 5-year | -3.9% | +10.3% | -37.5% | +89.4% | -0.6% | +40.6% |
| alltime | all time | -25.0% | +10.3% | -50.1% | +89.4% | -23.2% | +258.4% |
Aquestive Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $13.54 M(-32.6%) | $58.90 M(+0.9%) |
| June 2024 | - | $20.10 M(+66.8%) | $58.36 M(+13.3%) |
| Mar 2024 | - | $12.05 M(-8.7%) | $51.50 M(+1.8%) |
| Dec 2023 | $50.58 M(+6.1%) | $13.21 M(+1.6%) | $50.58 M(+5.3%) |
| Sept 2023 | - | $13.00 M(-1.8%) | $48.06 M(+3.3%) |
| June 2023 | - | $13.24 M(+18.9%) | $46.52 M(-0.1%) |
| Mar 2023 | - | $11.13 M(+4.2%) | $46.54 M(-2.4%) |
| Dec 2022 | $47.68 M(-6.2%) | $10.68 M(-6.8%) | $47.68 M(-0.8%) |
| Sept 2022 | - | $11.46 M(-13.6%) | $48.08 M(-3.7%) |
| June 2022 | - | $13.27 M(+8.1%) | $49.90 M(-4.0%) |
| Mar 2022 | - | $12.27 M(+10.8%) | $51.98 M(+2.3%) |
| Dec 2021 | $50.83 M(+10.9%) | $11.08 M(-16.6%) | $50.83 M(+8.4%) |
| Sept 2021 | - | $13.29 M(-13.4%) | $46.90 M(+12.0%) |
| June 2021 | - | $15.35 M(+38.0%) | $41.88 M(-13.1%) |
| Mar 2021 | - | $11.12 M(+55.6%) | $48.21 M(+5.1%) |
| Dec 2020 | $45.85 M | $7.15 M(-13.5%) | $45.85 M(-16.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | $8.26 M(-61.9%) | $55.12 M(-7.0%) |
| June 2020 | - | $21.68 M(+147.3%) | $59.28 M(+21.6%) |
| Mar 2020 | - | $8.77 M(-46.6%) | $48.73 M(-7.4%) |
| Dec 2019 | $52.61 M(-22.0%) | $16.42 M(+32.2%) | $52.61 M(-0.8%) |
| Sept 2019 | - | $12.42 M(+11.6%) | $53.01 M(-1.6%) |
| June 2019 | - | $11.13 M(-12.0%) | $53.86 M(-4.9%) |
| Mar 2019 | - | $12.64 M(-24.9%) | $56.66 M(-16.0%) |
| Dec 2018 | $67.43 M(+0.8%) | $16.82 M(+26.8%) | $67.43 M(+7.4%) |
| Sept 2018 | - | $13.27 M(-4.7%) | $62.80 M(-18.1%) |
| June 2018 | - | $13.93 M(-40.5%) | $76.68 M(+3.8%) |
| Mar 2018 | - | $23.41 M(+92.0%) | $73.89 M(+10.4%) |
| Dec 2017 | $66.92 M(+29.2%) | $12.20 M(-55.1%) | $66.92 M(+22.3%) |
| Sept 2017 | - | $27.15 M(+143.6%) | $54.72 M(+98.4%) |
| June 2017 | - | $11.14 M(-32.2%) | $27.58 M(+67.8%) |
| Mar 2017 | - | $16.44 M | $16.44 M |
| Dec 2016 | $51.78 M | - | - |
FAQ
- What is Aquestive Therapeutics annual revenue?
- What is the all time high annual revenue for Aquestive Therapeutics?
- What is Aquestive Therapeutics annual revenue year-on-year change?
- What is Aquestive Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly revenue year-on-year change?
- What is Aquestive Therapeutics TTM revenue?
- What is the all time high TTM revenue for Aquestive Therapeutics?
- What is Aquestive Therapeutics TTM revenue year-on-year change?
What is Aquestive Therapeutics annual revenue?
The current annual revenue of AQST is $50.58 M
What is the all time high annual revenue for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual revenue is $67.43 M
What is Aquestive Therapeutics annual revenue year-on-year change?
Over the past year, AQST annual revenue has changed by +$2.90 M (+6.09%)
What is Aquestive Therapeutics quarterly revenue?
The current quarterly revenue of AQST is $13.54 M
What is the all time high quarterly revenue for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly revenue is $27.15 M
What is Aquestive Therapeutics quarterly revenue year-on-year change?
Over the past year, AQST quarterly revenue has changed by +$540.00 K (+4.15%)
What is Aquestive Therapeutics TTM revenue?
The current TTM revenue of AQST is $58.90 M
What is the all time high TTM revenue for Aquestive Therapeutics?
Aquestive Therapeutics all-time high TTM revenue is $76.68 M
What is Aquestive Therapeutics TTM revenue year-on-year change?
Over the past year, AQST TTM revenue has changed by +$10.84 M (+22.56%)